Redeye believes current valuation implies a too cautious view of Abliva’s project portfolio. Early evidence and positive regulatory feedback validate the development of lead candidate KL1333 in primary mitochondrial disease, an untapped orphan drug opportunity. A key element to further successful clinical development and hence rerating, in our opinion, is if Abliva can secure additional financing.